Clinical and laboratory phenotype variability in type 2M von Willebrand disease

Essentials The pathophysiology of type 2M von Willebrand disease (VWD) is poorly understood. Sequence variations in type 2M VWD subjects were characterized. A high degree of clinical and laboratory variability exists within type 2M VWD variants. Some type 2M variants may share features of type 2A VWD.

[1]  J. Di Paola,et al.  Variable bleeding phenotype in an Amish pedigree with von Willebrand disease , 2016, American journal of hematology.

[2]  James C. Campbell,et al.  Mutational Constraints on Local Unfolding Inhibit the Rheological Adaptation of von Willebrand Factor* , 2015, The Journal of Biological Chemistry.

[3]  Junmei Chen,et al.  Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. , 2015, Blood.

[4]  D. Bellissimo,et al.  Crucial role for the VWF A1 domain in binding to type IV collagen. , 2015, Blood.

[5]  A. Chan,et al.  Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin , 2014, International journal of laboratory hematology.

[6]  S. Diamond,et al.  Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  J. Gill,et al.  Variability in platelet‐ and collagen‐binding defects in type 2M von Willebrand disease , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  R. Hoffmann,et al.  Collagen binding provides a sensitive screen for variant von Willebrand disease. , 2013, Clinical chemistry.

[9]  J. Gill,et al.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. , 2012, Blood.

[10]  P. Mannucci,et al.  Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients , 2012, Journal of thrombosis and haemostasis : JTH.

[11]  D. Bellissimo,et al.  VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. , 2012, Blood.

[12]  E. Favaloro.  Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[13]  R. Hoffmann,et al.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. , 2011, Blood.

[14]  B. Coller,et al.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders , 2010, Journal of thrombosis and haemostasis : JTH.

[15]  R. Hoffmann,et al.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. , 2010, Blood.

[16]  R. Hoffmann,et al.  Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD , 2010, Journal of thrombosis and haemostasis : JTH.

[17]  J. Scott,et al.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  R. Montgomery,et al.  Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage , 2009, Journal of thrombosis and haemostasis : JTH.

[19]  P. James,et al.  Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  J. Goudemand,et al.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). , 2007, Blood.

[21]  P. Mannucci,et al.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  S. Kitchen,et al.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. , 2006, Seminars in thrombosis and hemostasis.

[23]  F. Haverkate,et al.  An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. , 2006, Seminars in thrombosis and hemostasis.

[24]  J. Batlle,et al.  von Willebrand disease R1374C: Type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia) , 2005, American journal of hematology.

[25]  R. Liddington,et al.  Crystal Structure of the von Willebrand Factor A1 Domain and Implications for the Binding of Platelet Glycoprotein Ib* , 1998, The Journal of Biological Chemistry.

[26]  R. Montgomery,et al.  Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. , 1996, Blood.

[27]  J. Rand,et al.  150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. , 1991, The Journal of clinical investigation.

[28]  J. McPherson,et al.  Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. , 1987, The Journal of biological chemistry.

[29]  K. Titani,et al.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. , 1986, The Journal of biological chemistry.